Envision Healthcare (NYSE:EVHC)‘s stock had its “hold” rating reiterated by Stephens in a note issued to investors on Wednesday. They presently have a $34.00 price objective on the stock. Stephens’ target price points to a potential downside of 2.63% from the company’s previous close.

EVHC has been the subject of several other research reports. Bank of America lowered their price objective on shares of Envision Healthcare from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, October 9th. SunTrust Banks set a $55.00 price objective on shares of Envision Healthcare and gave the company a “buy” rating in a research report on Sunday, October 15th. Robert W. Baird reiterated a “buy” rating and set a $70.00 price target on shares of Envision Healthcare in a research report on Tuesday, October 17th. Cantor Fitzgerald cut shares of Envision Healthcare from an “overweight” rating to a “neutral” rating and set a $30.00 price target for the company. in a research report on Wednesday, November 1st. Finally, Jefferies Group set a $71.00 price target on shares of Envision Healthcare and gave the stock a “buy” rating in a research report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $40.73.

Shares of Envision Healthcare (EVHC) opened at $34.92 on Wednesday. The stock has a market cap of $4,220.00, a PE ratio of -23.44, a P/E/G ratio of 1.00 and a beta of 0.57. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.89. Envision Healthcare has a 1 year low of $23.77 and a 1 year high of $73.00.

Envision Healthcare (NYSE:EVHC) last announced its earnings results on Tuesday, October 31st. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.08). The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $2.03 billion. Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The company’s revenue for the quarter was up 142.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.13 EPS. analysts expect that Envision Healthcare will post 2.49 earnings per share for the current fiscal year.

Envision Healthcare declared that its Board of Directors has authorized a share buyback plan on Monday, September 18th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 4.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Picton Mahoney Asset Management lifted its position in shares of Envision Healthcare by 22.5% in the first quarter. Picton Mahoney Asset Management now owns 4,900 shares of the company’s stock worth $100,000 after purchasing an additional 900 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in Envision Healthcare by 11.9% during the second quarter. Daiwa Securities Group Inc. now owns 4,700 shares of the company’s stock worth $119,000 after buying an additional 500 shares during the last quarter. Seven Bridges Advisors LLC acquired a new position in Envision Healthcare during the third quarter worth $119,000. LS Investment Advisors LLC increased its holdings in Envision Healthcare by 23.8% during the second quarter. LS Investment Advisors LLC now owns 5,066 shares of the company’s stock worth $129,000 after buying an additional 974 shares during the last quarter. Finally, Commonwealth Bank of Australia increased its holdings in Envision Healthcare by 24.3% during the second quarter. Commonwealth Bank of Australia now owns 2,096 shares of the company’s stock worth $130,000 after buying an additional 410 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/10/envision-healthcare-evhc-stock-rating-reaffirmed-by-stephens.html.

Envision Healthcare Company Profile

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.